杜比实验室 DLB 深 沪
已收盘 08-01 16:00:00 美东时间
70.09
-5.250
-6.97%
华盛通- 最 高73.88
- 今 开73.07
- 成交量 81.89万股
- 最 低 69.23
- 昨 收 75.34
- 总市值 67.33亿
- 52周最高 89.00
- 市盈率 静 26.05
- 换手率 0.00%
- 52周最低 65.06
- 委 比 -33.33%
- 总股本 9606.62万
- 历史最高 100.03
- 量 比 2.52
- 振 幅 6.17%
- 历史最低 16.83
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $95 price target.
08-01 20:00
Dolby Laboratories declares $0.33 dividend
Dolby Laboratories, Inc. (NYSE:DLB) declares $0.33/share quarterly dividend, in line with previous. Forward yield 1.75% Payable Aug. 20; for shareholders of record Aug. 12; ex-div Aug. 12. The company...
08-01 16:57
【华鑫宏观策略】八月策略和十大金股
（来源：华鑫研究） ▌ 总量观点 核心要点：海外关注经济韧性、关税进展和9月降息预期。美股延续科技成长配置，左侧布局美债、黄金、美股中的地产、金融...
08-01 09:00
Dolby Laboratories Sees Q4 Adj EPS $0.61-$0.76 vs $0.77 Est; Sees Sales $288.000M-$318.000M vs $310.12M Est
Dolby Laboratories (NYSE:DLB) is looking for Q4 Adj EPS of $0.61-$0.76 vs $0.77 analyst estimate. sees sales of $288.000 million-$318.000 million vs $310.12 million analyst estimate.
08-01 04:17
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Dolby Laboratories, Inc. Q3 2025 Earnings Preview
Dolby Laboratories, Inc. (NYSE:DLB) is scheduled to announce Q3 earnings results on Thursday, July 31st, after market close. The consensus EPS Estimate is $0.71 (flat Y/Y) and the consensus Revenue Es...
07-31 00:49
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.
07-28 23:20
Lantern Pharma Reports Complete Metabolic Response In A Heavily Pre-Treated Lymphoma Patient With LP-284 In Its Phase 1 Clinical Trial
AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens.Complete response in an aggressive, recurring B-cell
07-23 19:58
FDA rejects Genentec's cancer drug label expansion
Genentech, part of the Roche Group (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF), announced that the U.S. FDA has rejected its request to expand the use of its cancer drug Columvi. The company had applied...
07-19 02:45
FDA改革释放创新红利！标普生物科技ETF(159502)盘中涨近2%
当地时间周三，美股市场盘中波动，三大指数最终集体收涨。截至收盘，标普500指数涨0.32%，纳指涨0.25%，道指涨0.53%。其中，纳指续创收盘新高。截至2...
07-17 11:34
